Close Menu

NEW YORK (GenomeWeb) – No longer a rumor, human germline editing with CRISPR/Cas9 is now the subject of a study published today in Protein & Cell. The results indicate that any therapeutic use of the technology in humans remains distant.

Scientists from Sun Yat-sen University in Guangzhou, China, led by Canquan Zhou and Junjiu Huang, used the CRISPR/Cas9 genome editing system in non-viable human zygotes to modify the gene that causes the hereditary blood disease beta-thalassemia.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.